A Grading System Based on Severity of Infection to Predict Mortality in Allogeneic Stem Cell Transplant Recipients

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Transplantation

• Publication date

  2006-07-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.tp.0000225762.54757.f7PMID 16861946
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Should Immunoglobulin Therapy Be Used in Allogeneic Stem-Cell Transplantation?

  2003cited by this paper
• Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy.

  2003cited by this paper
• Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy.

  2003cited by this paper
• Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

  2002cited by this paper
• Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

  2002cited by this paper
• Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study.

  2002cited by this paper
• 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer

  2002cited by this paper
• Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey

  2002cited by this paper
• Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

  2002cited by this paper
• Definitions of cytomegalovirus infection and disease in transplant recipients.

  2002cited by this paper
• A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation

  2001cited by this paper
• Severity of illness scores: Are they useful in febrile neutropenic adult patients in hematology wards? A prospective multicenter study

  2001cited by this paper
• A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia.

  2001cited by this paper
• Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation

  2001cited by this paper
• The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

  2000cited by this paper
• Toxoplasmosis after hematopoietic stem cell transplantation.

  2000cited by this paper
• Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants

  1999cited by this paper
• Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation.

  1999cited by this paper
• Methods for assessment of graft-versus-host disease.

  1998cited by this paper
• Fungal infections after marrow transplantation.

  1998cited by this paper
• IBMTR Severity INDEX FOR GRADING ACUTE GRAFT‐VERSUS‐HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE

  1997cited by this paper
• Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials.

  1997cited by this paper
• 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America.

  1997cited by this paper
• Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.

  1997cited by this paper
• Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation.

  1997cited by this paper
• GUIDELINES FROM THE INFECTIOUS DISEASES SOCIETY OF AMERICA 1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever

  1997influential reference
• Nosocomial coagulase-negative staphylococcal infections in bone marrow transplantation recipients with central vein catheter. A 5-year prospective study.

  1996cited by this paper
• Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. French Bacteremia-Sepsis Study Group.

  1996cited by this paper
• Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group.

  1994cited by this paper
• Toxoplasma gondii infection in marrow transplant recipients: a 20 year experience.

  1994cited by this paper
• Harmonisation in Pharmacovigilance

  1994cited by this paper
• Fluconazole Prophylaxis of Fungal Infections in Patients with Acute Leukemia: Results of a Randomized Placebo-Controlled, Double-Blind, Multicenter Trial

  1993cited by this paper
• Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow Transplant

  1993cited by this paper
• Pneumocystis carinii pneumonia in patients without AIDS.

  1993cited by this paper
• Pneumonia in allogenic and autologous bone marrow recipients. A retrospective study.

  1993cited by this paper
• Toxoplasmosis in bone marrow-transplant recipients: report of seven cases and review.

  1992cited by this paper
• Pulmonary infections after bone marrow transplant.

  1992cited by this paper
• Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group.

  1992cited by this paper
• Pneumocystis carinii pneumonitis following bone marrow transplantation.

  1992cited by this paper
• Candida infections in bone marrow transplant recipients.

  1991cited by this paper
• From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel.

  1990cited by this paper
• Infection with varicella-zoster virus after marrow transplantation.

  1985cited by this paper
• CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S

  1974cited by this paper

• Defining and Grading Infections in Clinical Trials Involving Hematopoietic Cell Transplantation: A Report from the BMT CTN Infectious Disease Technical Committee.

  2024cites this paper
• Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study

  2024cites this paper
• Long-term retention rate, adverse event temporal patterns and rescue treatment strategies of mycophenolate mofetil in systemic sclerosis: insights from real-life.

  2024cites this paper
• Faecal microbiota transplantation to prevent complications after allogeneic stem cell transplantation for haematological malignancies: a study protocol for a randomised controlled phase-II trial (the FMT-allo study)

  2023cites this paper
• Conditioning therapy with N‐acetyl‐L‐cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation

  2023cites this paper
• Efficacy and safety of Ruxolitinib in steroid-refractory/dependent chronic graft-versus-host disease: Real-world Data and Challenges.

  2021cites this paper
• Ibrutinib does not reverse disease- and treatment-related hypogammaglobulinaemia associated with chronic lymphocytic leukemia

  2021cites this paper
• Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease—results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health

  2020cites this paper
• Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

  2018cites this paper
• An Update on Calcineurin Inhibitor-Free Regimens: The Need Persists, but the Landscape has Changed.

  2016cites this paper
• Future Pathways for Immune Manipulation

  2014cites this paper
• The lack of memory B cells including T cell independent IgM+ IgD+ memory B cells in chronic graft‐versus host disease is associated with susceptibility to infection

  2012cites this paper
• Validation of a liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of Sotrastaurin and its metabolite N-desmethyl-sotrastaurin in human blood.

  2012cites this paper
• Sotrastaurin, a Protein Kinase C Inhibitor, Ameliorates Ischemia and Reperfusion Injury in Rat Orthotopic Liver Transplantation

  2011cites this paper
• Sotrastaurin, a Novel Small Molecule Inhibiting Protein‐Kinase C: Randomized Phase II Study in Renal Transplant Recipients

  2011cites this paper
• Sotrastaurin, a Novel Small Molecule Inhibiting Protein Kinase C: First Clinical Results in Renal‐Transplant Recipients

  2010cites this paper
• Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?

  2008cites this paper
• Advances in pathogenesis and management of sepsis

  2007cites this paper
• Emerging targets of biologic therapies for rheumatoid arthritis

  2007cites this paper
• Editorial introductions vii Editorial introductions. Nosocomial and hospital-related infections 345 Advances in pathogenesis and management of sepsis.

  2007cites this paper
• Preemptive antifungal therapy: still a way to go

  2006cites this paper